Jonathan Leitersdorf

X-Cell Medical, Inc. develops drugs for cardiovascular clinical applications. It focuses on delivery of drugs with safety and efficacy profiles for cardiovascular indications including restenosis, myocardial infarction and vulnerable plaque. The company was founded in 2002 and is headquartered in Monmouth Junction, NJ.

Outcome Capital LLC is a life sciences and healthcare advisory and investment banking firm that specializes in providing innovative companies with a value-added, market-aligned approach to mergers & acquisitions, partnering, and corporate finance. The firm was founded by Jonathan R. Wallace and is based in Boston, MA, with subsidiaries in the United States. The firm's multi-disciplinary team of industry experts draws from their broad relationships and a wide range of scientific, operational, strategic, and transactional expertise across the value chain to assist management teams and their boards in navigating both financial and corporate markets and implementing the best path for success.

NeurOptics, Inc. provides neurological patient care services. It offers npi-100 pupillometer, an hand-held and cordless device that removes subjectivity in the measurement of pupil size and the pupillary light reflex. The company was founded by Kamran Siminou and is headquartered in Irvine, CA.

Youdim Pharmaceuticals Ltd (Youdim Pharmaceuticals) is a venture capital subsidiary of XT Investments Ltd founded in 1997. The firm is headquartered in Yokneam, Israel.

Part of Clal Biotechnology Industries Ltd., Clal Life Sciences (CLS) LP is a venture capital fund.

XableCath, Inc. manufactures catheters for treatment of vascular diseases. The company was founded by Johannes B. Dahm and Lisa Jordan Dunlea in 2014 and is headquartered in Salt Lake City, UT.

ELT Sight, Inc. engages in the provision of healthcare services. It focuses on micro-invasive glaucoma surgery. The company is headquartered in Los Angeles, CA.

Caliber Therapeutics, Inc. is a holding company, which engages in the development of products for atherosclerotic diseases. It offers targeted angioplasty drug delivery balloon, a stent-free delivery platform of anti-restenotic drugs, which enables controlled and targeted drug delivery, reduces thrombosis risk, and reduces the need to implant permanent devices. The company was founded on August 3, 2009 and is headquartered in New Hope, PA.

Oxford Bioscience Partners is an Independent Venture Capital firm founded in 1992 by Edmund Martin Olivier, Alan G. Walton and Cornelius T. Ryan. The firm is headquartered in Boston.